Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG848

—

786585b3-971d-5fb4-9bc4-fb74cc740729

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • HEDGEHOG_SIGNALING+0.381
  • OXIDATIVE_PHOSPHORYLATION+0.358
  • WNT_BETA_CATENIN_SIGNALING+0.262
  • MITOTIC_SPINDLE+0.253
  • ADIPOGENESIS+0.177
  • NOTCH_SIGNALING+0.167
  • UNFOLDED_PROTEIN_RESPONSE+0.157
  • DNA_REPAIR+0.144
  • HYPOXIA+0.128
  • UV_RESPONSE_UP+0.115

Top 10 suppressed

  • INFLAMMATORY_RESPONSE-0.437
  • INTERFERON_GAMMA_RESPONSE-0.427
  • ALLOGRAFT_REJECTION-0.407
  • INTERFERON_ALPHA_RESPONSE-0.377
  • TNFA_SIGNALING_VIA_NFKB-0.367
  • IL6_JAK_STAT3_SIGNALING-0.302
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.257
  • E2F_TARGETS-0.228
  • PANCREAS_BETA_CELLS-0.209
  • SPERMATOGENESIS-0.202

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG219
mng-umap@100
——0.824
2SRR10900577
melanoma-umap@29
——0.824
39f9dec84-0c2c-4f85-8024-b8fb1de1eb81
colon-landscapes@1
——0.798
4MNG1260
mng-umap@100
——0.795
5TCGA-77-6843-01A-11R-1949-07
lung-landscapes@6
—cohortSQ20.787
6MNG460
mng-umap@100
——0.774
7MDT-AP-0602
medullo-epn-umap@date-based
MedMedulloblastoma0.767
828541e4e-2e2b-4772-9566-acf35b31a581
melanoma-umap@29
——0.761
9131546
medullo-epn-umap@date-based
EPNEPN Tumor0.749
1028E176DE-49DB-4F39-B022-C89235590CAC
brain-umap@2
——0.746

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HEDGEHOG_SIGNALING0.381Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.358Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.262Inavolisib— uncovered
MITOTIC_SPINDLE0.253Inavolisib— uncovered
ADIPOGENESIS0.177Inavolisib— uncovered
NOTCH_SIGNALING0.167Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.157Idelalisib— uncovered
DNA_REPAIR0.144Idelalisib— uncovered
HYPOXIA0.128Idelalisib— uncovered
UV_RESPONSE_UP0.115Idelalisib— uncovered
GLYCOLYSIS0.113Inavolisib— uncovered
PROTEIN_SECRETION0.100Remibrutinib— uncovered
MYOGENESIS0.068Inavolisib— uncovered
MYC_TARGETS_V20.065Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.061Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.055Inavolisib— uncovered
FATTY_ACID_METABOLISM0.040Inavolisib— uncovered
TGF_BETA_SIGNALING0.026Inavolisib— uncovered
ANGIOGENESIS0.023Remibrutinib— uncovered
MYC_TARGETS_V10.023Inavolisib— uncovered